Biosynex
ALBIO.PA operates in the healthcare services and equipment sector, providing medical equipment, supplies, and distribution services.
Business. ALBIO.PA is a healthcare company operating in the Medical Equipment, Supplies & Distribution industry, primarily engaged in the sale of medical products. The firm is headquartered in France and is listed on the Euronext Paris exchange under the ticker ALBIO.PA. Specific details regarding its operating segments and geographic revenue mix are not available.
At a glance
What drives this business
The watch-list the newsroom runs for this company — derived from its sector path, sharpened layer by layer. Not investment advice.
News & coverage
0Sector rotation
Developing storylines
Analysis
AI analysisOpportunity
Upcoming catalysts
Scheduled public events. Informational only — not investment advice.
- Macro
- Rate decisionBank of England rate decision (press conf.)2026-08-06 · GB
- Rate decisionReserve Bank of Australia rate decision (press conf.)2026-08-12 · AU
- Rate decisionNorges Bank rate decision (press conf.)2026-08-20 · NO
- Rate decisionSveriges Riksbank rate decision (press conf.)2026-09-03 · SE
- Rate decisionBank of Canada rate decision (press conf.)2026-09-09 · CA
- Rate decisionEuropean Central Bank rate decision (press conf.)2026-09-10 · EU
- Macro & political
- ElectionSE Swedish Election2026-09-14 · SE
- ElectionUS U.S. Midterms2026-11-03 · US
- ElectionFR French Legislative2027-06-01 · FR
Pre-earnings brief
Signals & dispatch
Composite-score breakdown
Synthesis
ALBIO.PA is a healthcare company operating in the Medical Equipment, Supplies & Distribution industry, primarily engaged in the sale of medical products. The firm is headquartered in France and is listed on the Euronext Paris exchange under the ticker ALBIO.PA. Specific details regarding its operating segments and geographic revenue mix are not available.
The company's capital structure is marked by a debt-to-equity ratio of 0.77, indicating a moderate reliance on debt financing. However, its liquidity position is weak, as evidenced by a current ratio of 0.71, which is below 1 and suggests that the company may struggle to meet its short-term obligations with its current assets. The company's free cash flow is negative at -26.65 million EUR, and its operating cash flow is also negative at -10.12 million EUR, signaling cash flow challenges.
Profitability metrics are concerning, with a return on equity of -53.78% and a return on assets of -22.26%, both significantly below the industry median for medical equipment and supplies. The company reported a net loss of 43.33 million EUR and an operating loss of 37.86 million EUR, indicating a lack of operational profitability.
The company's revenue is not segmented by geographic region or product line in the available data, so it is not possible to assess revenue concentration or geographic exposure. However, the lack of segment data limits the ability to evaluate the company's diversification and risk profile.
The company's growth trajectory is unclear due to the absence of historical revenue data in the input. However, the current financial performance, marked by declining profitability and negative cash flows, suggests a challenging operating environment. The outlook for the current fiscal year is not provided, but the company's financial position indicates a need for significant operational improvements.
The company's risk profile is elevated, with a medium liquidity risk and a negative net cash position after subtracting total debt. The dilution risk is assessed as low, and no adjustments have been applied to the valuation metrics. The company's financial performance and cash flow challenges suggest a need for close monitoring of its capital structure and liquidity position.
Recent events and filings are not detailed in the input data, so it is not possible to provide specific information on recent developments. The company's financial performance and risk profile suggest that investors should closely monitor its operational and financial disclosures in the near term.
- The company is operating at a net loss with a return on equity of -53.78% and a return on assets of -22.26%.
- The company's liquidity position is weak, with a current ratio of 0.71 and negative operating and free cash flows.
- The debt-to-equity ratio of 0.77 indicates a moderate reliance on debt financing.
- The company's financial performance and risk profile suggest a need for operational improvements and close monitoring of its capital structure.
Bull / Bear case
Generated · model-assistedIn focus — financials by report
Valuation
Revenue by segment
Business relationships
Supply chain
Peer comparison
Market position
Stress test
Predictor forecast
Options
Short squeeze
Earnings-call key lines
Estimate revisions
consensus EPS · 26-week trendSell-side observations
Themes
ESG
Risk factors
- Net cash is negative after subtracting total debt.
Benchmarks vs cohort
Corporate actions / M&A
FX exposure
Comparable transactions
Derivatives & instruments
Actions
Ask Handelsavisen
- Market data
- Market data cache
- Issuer disclosures
- Public news
- Earnings transcripts
- Consensus estimates
- ESG data
- Dilution Ratio(shares_outstanding_diluted - shares_outstanding_basic) / shares_outstanding_basic
- Net Cashcash_and_equivalents + short_term_investments - short_term_debt - long_term_debt
- Capex To Revenuecapital_expenditure / revenue
- Return On Equitynet_income / total_equity
- Debt To Equity(short_term_debt + long_term_debt) / total_equity
- Cash Conversion Ratiooperating_cash_flow / net_income
- ALBIO.PA Market data — financials · 2026-05-27
Ownership & reference
Leadership
- Larry AbensurChairman of the Board, Chief Executive Officer